Surufatinib for the Treatment of Advanced Pancreatic Neuroendocrine Tumors

The Lancet Oncology reported that SANET-p, a phase-III clinical trial, found that, in patients with advanced pancreatic neuroendocrine tumors, compared with placebo, surufatinib significantly improved progression-free survival. Surufatinib targets VEGFR-1, VEGFR-2, VEGFR-3, FGFR1 and CSF-1R and belongs to the anti-angiogenesis class as a new small-molecule inhibitor drug.
Study Details
This double-blind, multicenter study in China included 172 patients who had previously received 2 lines of systemic treatment for advanced, well-differentiated pancreatic neuroendocrine tumors. Between February 2016 and November 2019, patients were randomly assigned in a 2:1 ratio to receive oral surufatinib 300 mg once daily (113 patients) or placebo (59 patients) in consecutive 4-week cycles until disease progression, intolerable side effects or poor treatment adherence. Patients in the placebo group with disease progression were allowed to cross over to surufatinib.
The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population.
Progression-Free Survival Results
- A prespecified interim analysis was performed at a median follow-up of 19.3 months in the surufatinib group and 11.1 months in the placebo group.
- Median progression-free survival was 10.9 months in the surufatinib group (95% confidence interval [CI] = 7.5-13.8 months) and 3.7 months in the placebo group (95% CI = 2.8-5.6 months) (hazard ratio [HR] = 0.49, 95% CI = 0.32–0.76; P = 0.0011).
- The trial met the early stopping criteria at the interim analysis and was ended on the recommendation of the independent data monitoring committee because of the large difference between the surufatinib and placebo arms.
- On assessment by the blinded independent review committee, median progression-free survival was 13.9 months in the surufatinib group (95% CI = 11.0-24.9 months) and 4.6 months in the placebo group (95% CI = 3.6-7.4 months) (HR = 0.34, 95% CI = 0.21–0.55, P <0.0001).
- A total of 31 of the 59 placebo-group patients (53%) crossed over to receive surufatinib.
- Overall survival data were immature at the interim analysis; by the time of the analysis, 18% of patients in the surufatinib group and 15% in the placebo group had died.
Side Effects
- The most common severe (grade ≥ 3) treatment-related side effects in the surufatinib group were hypertension (38% in the surufatinib arm versus 7% in the placebo group), proteinuria (10% versus 2%) and hypertriglyceridemia (7% versus 0%).
- Serious treatment-related side effects were reported in 22% versus 7% of patients. The most frequently reported serious side effects in the surufatinib group were proteinuria in 4%, and ascites (fluid in the abdomen), diarrhea, gastrointestinal bleeding, vomiting and liver injury in 2%.
- Adverse events led to death in two patients in the surufatinib group, from gastrointestinal bleeding (considered possibly treatment-related) and cerebral hemorrhage.
Conclusion
Surufatinib significantly improves progression-free survival and has an acceptable safety profile in patients with progressive, advanced pancreatic neuroendocrine tumors, and may be a potential treatment option for this group.
*
Further Reading: What Is a Neuroendocrine Tumor?
The neuroendocrine system consists of hormone-producing (endocrine) cells and nerve cells. Neuroendocrine cells are mainly found in organs such as the digestive system (stomach and intestines) and lungs. Neuroendocrine tumors can occur throughout the body but frequently arise in neuroendocrine cells in the gastrointestinal system, lungs and pancreas. They are rare cancers as a group.

Most neuroendocrine tumors show no symptoms in their early stages and take years to grow. Some types, however, are aggressive and grow rapidly. This makes timely detection and control of the tumor difficult.
Standard treatment algorithm for locally advanced or metastatic pancreatic neuroendocrine tumors (NCCN guideline, 2018)

RELATED TOPICS:
- Lutetium 177 Received FDA Approval for the Treatment of Neuroendocrine Tumors
- Ho-166 Treatment Found Effective for Liver Metastases of Neuroendocrine Tumors
- Diagnosis and Current Treatment of Biologically Different Neuroendocrine Tumors
*
The video below can help explain pancreatic cancer types and treatments:
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.